Anti-TNFα therapy in the management of psoriasis: experience of a state referral center

Silva, Laura Maria Andrade; Rocha, Bruno de Oliveira; Nobre, Ana Cláudia Pinto; Rêgo, Vitória Regina Pedreira de Almeida; Follador, Ivonise; Oliveira, Maria de Fátima Santos Paim de

doi:10.1590/abd1806-4841.20142613

Cited by 2 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another case series at a state referral centre in Brazil included 74 psoriatic patients treated with anti‐TNF alpha. It found that 95.9% of patients had been treated with traditional therapies before the administration of biologics . Forty‐nine individuals (66.2%) were treated simultaneously with methotrexate, in doses ranging from 10 to 15 mg/week.…”

Section: Resultsmentioning

confidence: 99%

“…It found that 95.9% of patients had been treated with traditional therapies before the administration of biologics. 32 Forty-nine individuals (66.2%) were treated simultaneously with methotrexate, in doses ranging from 10 to 15 mg/week. The main reason for therapy with biologics was an insufficient response to standard therapies (55.4%).…”

Section: Treatment Patternmentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis in Latin America and the Caribbean: a systematic review

Hernández-Vasquéz

Molinari

Larrea

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease that generally affects the skin, nails and joints. The burden of psoriatic disease in Latin America and the Caribbean (LAC) remains largely unknown. To estimate the burden of psoriasis in LAC. We conducted a systematic review following the MOOSE and PRISMA statements. We searched published studies in MEDLINE, EMBASE, LILACS and CENTRAL from 1st January 2000 to 5th August 2015. We included studies that reported incidence, prevalence, health resource use and health expenditures, treatment patterns, comparative effectiveness of different drugs, patients reported outcomes, adherence to treatment and patient preferences in LAC. Risk of bias was assessed evaluating selection of participants, control of cofounders, measurement of exposure and outcome and conflict of interest. Pairs of reviewers independently selected, extracted and assessed the bias risk of the studies. The systematic review was registered at PROSPERO (CRD42016038325). A total of 18 studies from 12 LAC countries were included. Most were observational studies, between which there was a large heterogeneity of outcomes. Population-based studies were not found and most data came from hospital registries. One study reported an incidence of psoriatic arthritis in 6.26 cases per 100 000 person-years. Another study found an incidence of psoriasis 1020 per 100 000 patient-year attending at a dermatology clinic. The prevalence reported in the Argentinean health service was 74 cases per 100 000. Further, psoriasis has been shown to have a substantial negative impact on quality of life. A number of studies also indicated that non-communicable disease burden increases with the presence and severity of psoriasis. With regard to treatment pattern, methotrexate was the dominant systemic therapy. In conclusion, there is an important lack of information from LAC concerning the burden of psoriasis. Further studies investigating the burden of psoriasis in representative LAC populations are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Treatment Patternmentioning

confidence: 99%

Psoriasis in Latin America and the Caribbean: a systematic review

Hernández-Vasquéz

Molinari

Larrea

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The available studies that focused on comorbidities are listed in Table 2 . Silva et al 7 evaluated the profile of psoriasis patients using biological drugs. The main indications for biological therapy were a poor response to other systemic treatments (55.4%) and a psoriatic arthritis diagnosis (81.1%).…”

Section: Epidemiology and Comorbidities Of Psoriasis In Brazilian Patmentioning

confidence: 99%

Epidemiology and treatment of psoriasis: a Brazilian perspective

Duarte¹,

Porto-Silva²,

Oliveira³

2015

PTT

View full text Add to dashboard Cite

Psoriasis is a chronic immune-mediated systemic disease that is influenced by genetic and environmental factors, is associated with comorbidities, and has a negative impact on the quality of life of affected individuals. The prevalence of psoriasis varies among different ethnic groups, but this topic has not been studied in Brazil to date. In this review, we evaluate the epidemiology and treatment of psoriasis from a Brazilian perspective. We focused on studies that involved Brazilian subjects. The prevalence of psoriasis in Brazil is estimated to be 2.5%, but no population study has been performed previously. Environmental factors, such as tropical climate, in association with genetic factors, such as miscegenation, may exert a beneficial impact on the course and frequency of psoriasis in Brazil. A number of studies have advanced our understanding of the cardiovascular, ophthalmic, and oral comorbidities that are associated with psoriasis. Concerns about biological therapy, such as endemic leprosy, human T-cell lymphotropic virus (HTLV), and tuberculosis infections, are discussed. The nonavailability of treatment options for psoriasis in the public health system contradicts the Brazilian Society of Dermatology guidelines, stimulating the judicialization of access to medicines in psoriasis care.

show abstract

Anti-TNFα therapy in the management of psoriasis: experience of a state referral center

Cited by 2 publications

References 15 publications

Psoriasis in Latin America and the Caribbean: a systematic review

Psoriasis in Latin America and the Caribbean: a systematic review

Epidemiology and treatment of psoriasis: a Brazilian perspective

Contact Info

Product

Resources

About